All Press releases

November 10, 2017

Fulcrum Therapeutics to Present at the Annual Society for Neuroscience Meeting

October 11, 2017

Fulcrum Therapeutics to Present at the 18th Annual Fragile X and Related Neurodevelopmental Disorders Workshop

September 25, 2017

Fulcrum Therapeutics to Present at the 10th Annual BioPharm America International Partnering Conference

September 5, 2017

Fulcrum Therapeutics to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference

August 9, 2017

Fulcrum Therapeutics Named Finalist for the 2017 Xconomy Awards in the Patient Partnership Category

May 10, 2017

Fulcrum Therapeutics Announces Additional Series A Financing from GV

May 3, 2017

Fulcrum Therapeutics Expands Leadership Team with Appointment of Owen Wallace, Ph.D., as Chief Scientific Officer and Amit Hasija as Chief Business Officer

February 7, 2017

Fulcrum Therapeutics Strengthens its Board of Directors with the Addition of Alan Ezekowitz, MBChB, D.Phil., and James J. Collins, Ph.D.

December 7, 2016

Fulcrum Therapeutics Appoints Renowned Experts in CNS Disorders and Muscular Dystrophies to Serve on Newly Formed Scientific Advisory Board

September 19, 2016

FierceBiotech names Fulcrum Therapeutics as one of its “Fierce 15” Biotech Companies of 2016

Prev
Next